School of Pharmacy

Qingcheng Mao

Associate Professor

Department of Pharmaceutics, OPRU, Pharmaceutics Faculty, UWPKDAP

Telephone: (206) 685-0355


Website: PubMed


  • PhD, University of Bern, Switzerland
  • Master of Science, Bachelor of Science, East China University of Science and Technology

Research Interests

ABC protein-mediated transport of endogenous substances, drugs and xenobiotics; Expression and activity of drug transporters and metabolizing enzymes in the feto-placental unit and their impact on fetal exposure to drugs and xenobiotics; Regulation of ABC transporters in human placenta by hormones and xenobiotics.

Current projects: 1) Understanding the effects of cannabinoids on placental trophoblast differentiation and fetal growth through in vitro and in vivo studies; 2) Understanding the role of drug transporters in determining fetal exposure to cannabinoids; 3) Unveiling impact of gut microbiome on maternal-fetal drug disposition during pregnancy.


Dr. Mao’s primary research interests focus on ABC transporter-mediated transport of drugs and xenobiotics and the mechanisms by which pregnancy affects drug/xenobiotic disposition including fetal drug/xenobiotic exposure through regulation of expression and activity of drug disposition genes. He has published some important findings in these areas; and his research has been supported by the National Institutes of Health grants. He received his bachelor and master from East China University of Science and Technology in Shanghai, China; and doctorate from the University of Bern in Switzerland. He was a postdoctoral fellow at the University of North Carolina in Chapel Hill and Queen’s University in Canada.

Dr. Mao is an active member of American Association of Pharmaceutical Scientists, American Society for Pharmacology and Experimental Therapeutics, American Physiological Society, and American Association for the Advancement of Science. He serves on the editorial boards of “Drug Metabolism and Disposition” and “International Journal of Biochemistry and Molecular Biology“.

Selected Publications

Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, Mao Q. The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol. 73(3):949-959, 2008

Shuster DL, Bammler TK, Beyer RP, Macdonald JW, Tsai JM, Farin FM, Hebert MF, Thummel KE, Mao Q. Gestational age-dependent changes in gene expression of metabolic enzymes and transporters in pregnant mice. Drug Metab Dispos. 41(2):332-342, 2013

Shuster DL, Risler LJ, Liang CK, Rice KM, Shen DD, Hebert MF, Thummel KE, Mao Q. Maternal-fetal disposition of glyburide in pregnant mice is dependent on gestational age. J Pharmacol Exp Ther. 350(2):425-434, 2014

Shuster DL, Risler LJ, Prasad B, Calamia JC, Voellinger JL, Kelly EJ, Unadkat JD, Hebert MF, Shen DD, Thummel KE, Mao Q. Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 92(4):690-700, 2014

Neradugomma NK, Liao MZ, Mao Q. Buprenorphine, Norbuprenorphine, R-Methadone, and S-Methadone Upregulate BCRP/ABCG2 Expression by Activating Aryl Hydrocarbon Receptor in Human Placental Trophoblasts. Mol Pharmacol. 91(3):237-249, 2017

Liao MZ, Gao C, Shireman LM, Phillips B, Risler LJ, Neradugomma NK, Choudhari P, Prasad B, Shen DD, Mao Q. P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine. Pharmacol Res. 119:61-71, 2017

Liao MZ, Gao C, Phillips BR, Neradugomma NK, Han LW, Bhatt DK, Prasad B, Shen DD, Mao Q. Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation. Drug Metab Dispos. 46(2):100-108, 2018